Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 7

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 7
---
 pursued with each 
 product candidate;                                                                                                |

| • |     | the anticipated progress in our current and future clinical trials; |

| • |     | plans and strategies to create novel technologies; |

| • |     | the scope of protection we are able to establish and maintain for intellectual property rights covering our 
 technology platforms and product candidates, and the defense of such intellectual property rights;          |

iii

| • |     | developments relating to our competitors and our industry, including competing product candidates, therapies and 
 laboratory tests;                                                                                                |

| • |     | future development and/or expansion of our product candidates, therapies and laboratory tests in our markets; |

| • |     | sources of competition for any of our product candidates or laboratory tests; |

| • |     | our ability to generate revenue and the sources of such revenue; |

| • |     | our ability to effectively manage our gross profit margins; |

| • |     | our potential need for additional financing and the availability thereof; |

| • |     | our ability to continue as a going concern; |

| • |     | our ability to remain listed on Nasdaq; |

| • |     | our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to 
 obtain additional capital;                                                                                    |

| • |     | our ability to repay or refinance some or all of our outstanding indebtedness and our ability to raise capital in 
 the future;                                                                                                       |

| • |     | our ability to integrate into our business and operations, develop, fully utilize and monetize acquired assets; |

| • |     | our ability to transfer the drug product manufacturing to a contract drug manufacturing organization; |

| • |     | the potential enhancement of our cash position through development, marketing, and licensing arrangements; |

| • |     | the implementation of our business model, strategic plans for our business, and product candidates; |

| • |     | our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; |

| • |     | our ability to prevent or timely detect a material security breach or cyber security attack affecting our 
 operations and property;                                                                                  |

| • |     | our use of the proceeds from any exercise of the Warrants; and |

| • |     | other factors detailed under the section entitled “Risk Factors” in this prospectus. |

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition